Gold Nanoparticles to Improve HIV Drug Delivery

Garrido, Carolina; Simpson, C.J.S.M.; Dahl, Noelle P.; Bresee, Jamee; Whitehead, Daniel C.; Lindsey, Erick A.; Harris, Tyler; Smith, Candice A.; Carter, Carly J.; Feldheim, Daniel L.; Melander, Christian; Margolis, David M.

doi:10.4155/fmc.15.57

Cited by 64 publications

(54 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…59 While free RAL demonstrates better HIV suppression, the RAL-AuNPs did exhibit better cellular uptake, BBB penetration, and accumulation in the spleen and brain. 59 The accumulation in viral reservoirs was accompanied by increased off-site accumulation in the liver, kidneys, lungs, and heart. 59 Another proposed delivery system of glyceryl monostearatemodified, nevirapine loaded gold shell NPs displayed similar increased uptake by PBMCs and sustained accumulation in viral reservoirs such as the spleen, lymph nodes, thymus, bone marrow, and brain.…”

Section: Inorganic Npsmentioning

confidence: 95%

“…Neither SDC‐1721 or AuNPs exhibited independent suppression of viral replication, but the multivalent SDC‐1721 AuNPs inhibited viral replication with an average IC 50 value of 10 nM, matching the average IC 50 value of maraviroc . The uptake of 2–10 nm AuNPs by macrophages, PBMCs, and human‐brain micro‐vascular endothelial cells (HBMECs) and the accumulation of unmodified AuNPs in the spleen and, to a much lesser extent, the brain, was reported . By conjugating thiolated raltegravir (RAL), an inactive form of RAL, to AuNPs in a 4:1 ratio, the researchers were able to suppress viral replication to 25.23% .…”

Section: Nanostructured Systems For the Treatment Of Hivmentioning

confidence: 99%

“…While free RAL demonstrates better HIV suppression, the RAL‐AuNPs did exhibit better cellular uptake, BBB penetration, and accumulation in the spleen and brain . The accumulation in viral reservoirs was accompanied by increased off‐site accumulation in the liver, kidneys, lungs, and heart …”

Section: Nanostructured Systems For the Treatment Of Hivmentioning

confidence: 99%

See 2 more Smart Citations

Harnessing nanostructured systems for improved treatment and prevention of HIV disease

Monroe

Flexner

Cui

2018

Bioengineering & Transla Med

View full text Add to dashboard Cite

Combination antiretroviral therapy effectively controls human immunodeficiency virus (HIV) viral replication, delaying the progression to acquired immune deficiency syndrome and improving and extending quality of life of patients. However, the inability of antiretroviral therapeutics to target latent virus and their poor penetration of viral reserve tissues result in the need for continued treatment for the life of the patient. Side effects from long‐term antiretroviral use and the development of drug resistance due to patient noncompliance are also continuing problems. Nanostructured systems of antiretroviral therapeutics have the potential to improve targeted delivery to viral reservoirs, reduce drug toxicity, and increase dosing intervals, thereby improving treatment outcomes and enhancing patient adherence. Despite these advantages, very few nanostructured antiretroviral delivery systems have made it to clinical trials due to challenges in preclinical and clinical development. In this context, we review the current challenges in HIV disease management, and the recent progress in leveraging the unique performance of nanostructured systems in therapeutic delivery for improved treatment and prevention of this incurable human disease.

show abstract

Section: Inorganic Npsmentioning

confidence: 95%

Section: Nanostructured Systems For the Treatment Of Hivmentioning

confidence: 99%

See 1 more Smart Citation

Harnessing nanostructured systems for improved treatment and prevention of HIV disease

Monroe

Flexner

Cui

2018

Bioengineering & Transla Med

View full text Add to dashboard Cite

show abstract

“…The drug is usually made from natural polymer material and has been fully applied to treatment course of tumor, diabetes and vascular disease. It can effectively extend action time of drug, then effectively improve clinical effect of the drug and minimize toxic and side effects of the drug [7] . Frequency of use of nano preparation technology can provide better development space for medical use and effectively promote long-term development of nano biotechnology.…”

Section: Carbon Materialsmentioning

confidence: 99%

The Research Progress of Targeted Drug Delivery Systems

Zhan

Ting

Zhu

2017

IOP Conf. Ser.: Mater. Sci. Eng.

View full text Add to dashboard Cite

Abstract. Targeted drug delivery system (DDS) means to selectively transport drugs to targeted tissues, organs, and cells through a variety of drugs carrier. It is usually designed to improve the pharmacological and therapeutic properties of conventional drugs and to overcome problems such as limited solubility, drug aggregation, poor bio distribution and lack of selectivity, controlling drug release carrier and to reduce normal tissue damage. With the characteristics of nontoxic and biodegradable, it can increase the retention of drug in lesion site and the permeability, improve the concentration of the drug in lesion site.at present, there are some kinds of DDS using at test phase, such as slow controlled release drug delivery system, targeted drug delivery systems, transdermal drug delivery system, adhesion dosing system and so on. This paper makes a review for DDS.

show abstract

“…Further, such particles can be fabricated to display conjugates of raltegravir, an HIV integrase inhibitor, and inhibit viral replication. Finally AuNPs cross the BBB and can be found in the brain parenchyma in mice (Garrido et al , 2013)…”

mentioning

confidence: 99%

Translational challenges in targeting latent HIV infection and the CNS reservoir problem

Garrido

2014

J. Neurovirol.

Self Cite

View full text Add to dashboard Cite

Too controversial to discuss only a short time ago, achieving a cure for HIV infection has become a priority in HIV research. However, substantial challenges must be overcome. Among key hurdles to be surmounted is the definition of a reliable, validated model in which to test latency reversal agents (LRAs), as current primary cell models differ in their response to such agents. Animal models such as the HIV-infected humanized BLT mouse and SIV-infected macaque will be essential to study LRAs, and to quantify their effects in anatomic reservoirs. Of several potential anatomic reservoirs, the central nervous system presents a significant obstacle, as it is known to harbor persistent HIV infection, and is difficult to access for study and therapeutic intervention.

show abstract

Gold Nanoparticles to Improve HIV Drug Delivery

Cited by 64 publications

References 41 publications

Harnessing nanostructured systems for improved treatment and prevention of HIV disease

Harnessing nanostructured systems for improved treatment and prevention of HIV disease

The Research Progress of Targeted Drug Delivery Systems

Translational challenges in targeting latent HIV infection and the CNS reservoir problem

Contact Info

Product

Resources

About